Factors associated with initiation and persistence of urate-lowering therapy

Table 3 Predictors for not adhering to ULT

		Predictors for not persisting with ULT after 125 days^a (Log)
	% with event	Univariate odds ratio 95% CI	Multivariate^b odds ratio 95% CI (with eGFR)	Multivariate^c odds ratio 95% CI (with renal disease)
Male (ref)	37.47
Female	36.30	0.95 (0.78–1.16)	0.89 (0.71–1.13)	0.92 (0.75–1.13)
Age, years
20–49 (ref)	54.29
50–59	37.65	0.51 (0.36–0.73)	0.50 (0.31–0.79)	0.54 (0.38–0.77)
60–69	37.31	0.50 (0.37–0.68)	0.63 (0.42–0.95)	0.58 (0.42–0.80)
70–79	33.28	0.42 (0.31–0.57)	0.59 (0.39–0.91)	0.51 (0.37–0.71)
80–	32.55	0.41 (0.30–0.56)	0.70 (0.44–1.11)	0.52 (0.36–0.74)
MCCI
0 (ref)	43.65
1–2	32.67	0.63 (0.51–0.76)	0.75 (0.59–0.96)	0.74 (0.60–0.92)
>2	30.16	0.56 (0.42–0.73)	0.71 (0.52–0.99)	0.69 (0.51–0.93)
Renal disease
0 (ref)	38.54
1	29.57	0.67 (0.52–0.86)	0.74 (0.57–0.97)
eGFR >60 mL/min/1.73 m² “normal kidney function” (ref)	41.62
eGFR 60–31 mL/min/1.73 m² “reduced kidney function”	31.19	0.64 (0.51–0.79)		0.68 (0.53–0.87)
eGFR 30–10 mL/min/1.73 m² ^“severely reduced kidney function”	28.57	0.56 (0.37–0.85)		0.59 (0.37–0.92)
eGFR <10 mL/min/1.73 m² “end-stage kidney failure”	25.00	0.47 (0.05–4.51)		0.53 (0.05–5.11)
2011, ref	37.40
2012	33.87	0.86 (0.69–1.06)
2013	41.62	1.19 (0.95–1.50)

ULT urate-lowering treatment, CI confidence interval, eGFR estimated glomerular filtration rate, MCCI metabolic cardiovascular comorbidity index
^aDefined as no ULT dispensation 125 days after last dispensation
^bAdjusted for sex, age, comorbidities, and eGFR
^cAdjusted for sex, age, comorbidities and renal disease

ISSN: 1478-6362